Latest Industry Insights

Dr. Eric Kelsic, CEO and co-founder of Dyno Therapeutics, explains how AI could reduce the cost of gene therapy delivery to $0.

The Discovery Spark program aims to help upcoming biotechnology and healthcare companies grow. In this article, we take a closer look at some of the innovative technologies of this year's Discovery Spark cohort.

In this interview, Simon Wieninger discusses the critical role digital tools play in improving bioprocessing efficiency, how cloud technologies and data harmonization can overcome key challenges and the importance of maintaining robust data security.

We reached out to start-ups at ELRIG Drug Discovery 2024 to see how AI and bioengineering can be applied in biotech and drug discovery.

In this interview, Dr. Jonathan Jacobs, who leads ATCC’s Sequencing & Bioinformatics Center, discusses how data provenance influences data integrity in scientific research and how a lack of standardization can lead to issues like data poisoning.

In an interview, Nicole Brockway, president of biologicals and chemicals at Thermo Fisher Scientific, discusses how the company is addressing the challenges of modern therapeutic manufacturing and what innovations lie ahead in bioproduction.

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.

This article will detail the quantitative and qualitative benefits of adopting digital twin technology throughout the different steps of battery production.

In bioanalysis, AI could alleviate preclinical and clinical bioanalytical data processing and analysis. Here, Mary Belfast from Teva Branded Pharmaceuticals, discusses some of the latest guidelines on AI implementation and validation in bioanalysis.

We sat down with Professor Peter Van Eenoo, director of the Doping Control Laboratory (DoCoLab), part of the University of Ghent, Belgium, to discuss the intricacies of anti-doping testing and the challenges faced in catching sporting cheats.